Fibrinogen degradation by hementin, a fibrinogenolytic anticoagulant from the salivary glands of the leech Haementeria ghilianii
Research article published in The Journal of laboratory and clinical medicine (1984)
Resumen
The leech Haementeria ghilianii contains the anticoagulant hementin in its salivary glands, which renders ingested blood incoagulable. The loss of thrombin-coagulability of human fibrinogen, plasma, and blood was dependent on both dose and time, and it was attributable to direct proteolytic degradation of fibrinogen (Mr 340,000) by hementin. Using purified fibrinogen as the substrate, it was demonstrated that the enzyme cleaved with equal probability either through all three chains in the connector region between the D and E structural domains or in the COOH-terminal of the A alpha chain. The degradation pattern of fibrinogen in blood and purified counterpart was the same in respect to the types of degradation products formed and the rate of proteolysis. Three pairs of fibrinogen degradation products characterized by Mr were distinguished: 320,000 and 300,000, 225,000 and 200,000, 157,000 and 132,000. In each pair, the heavier product had the intact COOH-terminals of the A alpha, B beta, and gamma chains. Of special interest was the derivative of Mr 225,000 because it contained the intact A alpha, B beta, and gamma chains of the original fibrinogen. Hementin cleaved non-cross-linked and cross-linked fibrin clots; however, the rate of proteolysis was much slower than that of fibrinogen. Individual carboxymethylated chains of fibrinogen were not degraded by the enzyme. Hementin abolished coagulability of fibrinogen by a limited proteolysis that disassembled functionally bivalent polymerization sites. In addition, fibrin clot formation was inhibited by fibrinogen fragments generated by hementin. The enzyme appeared to have a unique and limited specificity for a few peptide bonds projected in the tertiary structure of the native fibrinogen molecule.
Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.
El resumen se deja sin traducir para conservar la redacción original de los autores.
Síntesis
Hementin, the anticoagulant from the salivary glands of Haementeria ghilianii, abolished thrombin coagulability of human fibrinogen, plasma and blood through limited, dose- and time-dependent proteolysis at a few specific bonds, and the resulting fragments also inhibited fibrin clot formation.
Por qué esto importa para la hirudoterapia
Este estudio de bioquímica in vitro (Malinconico et al., 1984) caracterizó la hementina, un anticoagulante de las glándulas salivales de la sanguijuela Haementeria ghilianii, mostrando que anula la capacidad de coagulación trombínica del fibrinógeno humano, el plasma y la sangre mediante una degradación proteolítica directa dependiente de la dosis y del tiempo, en lugar de a través de la inhibición trombínica, y que también puede lisar coágulos de fibrina no entrecruzados y entrecruzados, aunque más lentamente. Es una entrada fundacional en la historia de descubrimiento de fármacos del secretoma de sanguijuelas medicinales, documentando un mecanismo fibrinogenolítico distinto de los inhibidores trombínicos tipo hirudin más familiares a partir de Hirudo medicinalis e ilustrando la diversidad química de los anticoagulantes derivados de sanguijuelas. Nota: estos son experimentos con enzimas purificadas y sangre ex vivo de una especie de sanguijuela no medicinal, sin datos animales o clínicos, por lo que los hallazgos se refieren al mecanismo y al potencial de descubrimiento de fármacos, no a la hirudoterapia clínica.
Compuestos relacionados del registro de la ASH
Moléculas de la sanguijuela y fármacos derivados de la hirudina relacionados con el tema de este artículo, cada uno con un perfil completo en el registro de compuestos de la ASH:
Citación
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Investigación relacionada
Más estudios revisados por pares en la categoría «Ensayos clínicos».
- Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
- Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
- Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
- Efficacy and Safety of Hirudotherapy for Improving Sperm Quality Parameters in Male Infertility: A Randomized Controlled Trial — Abtahi-Forooshani M et al. (2026)
- Reverse Sural Flap Venous Congestion Successfully Managed With Enoxaparin in a Male Patient With a Traumatic Foot Crush Injury: A Case Report — Velasco-Bustamante J et al. (2026)
- Investigación de los efectos terapéuticos del tratamiento con sanguijuelas medicinales sobre la lesión por isquemia-reperfusión de la extremidad inferior — Ünal K et al. (2026)
- Efficacy of Medicinal Leech Therapy in Diverse Clinical Applications: A Comprehensive Study from Azerbaijan — Farzali S et al. (2025)
- HIRUDOTHERAPY IN RECONSTRUCTIVE SURGERY: CASE-REPORTS AND REVIEW — Heinz P et al. (2020)
- Hirudoterapia en la cicatrización de heridas — Nair H et al. (2022)
- Improvement of patient care through hirudotherapy and the management of leeches from their reception to their disposal in France — Vaesken C et al. (2023)
Añadido a la biblioteca ASH: 28 de mayo de 2026 · Última actualización del sitio: 18 de junio de 2026